Market Cap 520.30M
Revenue (ttm) 170.44M
Net Income (ttm) -193.88M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -113.75%
Debt to Equity Ratio 0.00
Volume 1,329,336
Avg Vol 808,860
Day's Range N/A - N/A
Shares Out 51.62M
Stochastic %K 60%
Beta 1.12
Analysts Strong Sell
Price Target $29.25

Company Profile

REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202 for the treatment...

Industry: Biotechnology
Sector: Healthcare
Phone: 240 552 8181
Address:
9804 Medical Center Drive, Rockville, United States
maphere
maphere May. 13 at 6:38 PM
$RGNX ABBVIE investing big $$$ into the PH3 wAMD trial, look at the global sites being added and preparing for commercialization. Abbvie doesn't say much at their ER about this but this is where a lot of $$$ is going right now. Hope to hear some news tomorrow. https://clinicaltrials.gov/study/NCT07007065?term=abbv-rgx-314&viewType=Card&rank=5&tab=history&a=60&b=61&compareMode=sideBySide#version-content-panel
3 · Reply
explover
explover May. 13 at 5:09 PM
$RGNX so basically if interim results (n=13) from March 11, 2026 replicate on the pivotal sample (n=30), this goes to $18-24 on day one and then further I suppose we are afraid of a single SAE?
1 · Reply
cold_beef_cake
cold_beef_cake May. 13 at 3:52 PM
$RGNX Not trading like a company that's about to hit it out of the park.
2 · Reply
RobbyAxelrod1
RobbyAxelrod1 May. 13 at 3:40 PM
$RGNX Sold ill wait for tomorrow usually news seeps in by now doesn't look to good here.
2 · Reply
maphere
maphere May. 13 at 2:37 PM
$RGNX Another webinar on the 19th...3 hours long.
1 · Reply
murphylaw
murphylaw May. 13 at 2:24 PM
$RGNX should be $12 by 4PM?
1 · Reply
buymoremakemore
buymoremakemore May. 12 at 11:45 PM
$RGNX Rarely any bears on here coming into data readout. Short float 15%. Not bad
0 · Reply
Timefortendies77
Timefortendies77 May. 12 at 10:55 PM
$RGNX Hi RGNX ---it's your pals over at $BHVN. What's the word on getting your drug reassessed given the change in FDA leadership?
2 · Reply
Timefortendies77
Timefortendies77 May. 12 at 10:53 PM
$BHVN Remember this tweet? @US_FDA exploring path forward for therapies that received CRLs $BHVN , $RGNX , Sydnexis held meetings w FDA’s chief counsel, Sean Keveney, following high-profile regulatory setbacks. Such meetings are highly unusual, writes BioCentury Washington Editor https://x.com/jeff_cranmer/status/2039127714599440671
0 · Reply
murphylaw
murphylaw May. 12 at 5:59 PM
$RGNX Epic pop in store tomorrow. Buckle up!
0 · Reply
Latest News on RGNX
Shareholders Sue RGNX Over Gene Therapy Study Claims

2026-03-24T15:47:52.000Z - 7 weeks ago

Shareholders Sue RGNX Over Gene Therapy Study Claims


REGENXBIO Transcript: Leerink Global Healthcare Conference 2026

Mar 9, 2026, 9:20 AM EDT - 2 months ago

REGENXBIO Transcript: Leerink Global Healthcare Conference 2026


Regenxbio price target lowered to $42 from $45 at Stifel

2026-03-05T19:15:21.000Z - 2 months ago

Regenxbio price target lowered to $42 from $45 at Stifel


REGENXBIO Earnings Call Transcript: Q4 2025

Mar 5, 2026, 8:00 AM EST - 2 months ago

REGENXBIO Earnings Call Transcript: Q4 2025


Regenxbio reports Q4 EPS ($1.30) vs. ($1.01) last year

2026-03-05T12:15:47.000Z - 2 months ago

Regenxbio reports Q4 EPS ($1.30) vs. ($1.01) last year


REGENXBIO to Participate in Upcoming Investor Conferences

Mar 2, 2026, 7:05 AM EST - 2 months ago

REGENXBIO to Participate in Upcoming Investor Conferences


US FDA declines to approve Regenxbio's rare disease drug

Feb 9, 2026, 4:13 PM EST - 3 months ago

US FDA declines to approve Regenxbio's rare disease drug


REGENXBIO Announces Regulatory Update on RGX-121 BLA for MPS II

Feb 9, 2026, 4:05 PM EST - 3 months ago

REGENXBIO Announces Regulatory Update on RGX-121 BLA for MPS II


US FDA places clinical hold on Regenxbio's gene therapy trials

Jan 28, 2026, 7:46 AM EST - 3 months ago

US FDA places clinical hold on Regenxbio's gene therapy trials


REGENXBIO Announces Regulatory Update on Ultra Rare MPS Programs

Jan 28, 2026, 7:30 AM EST - 3 months ago

REGENXBIO Announces Regulatory Update on Ultra Rare MPS Programs


REGENXBIO to Participate in Upcoming Investor Conference

Nov 25, 2025, 7:05 AM EST - 6 months ago

REGENXBIO to Participate in Upcoming Investor Conference


REGENXBIO Transcript: Stifel 2025 Healthcare Conference

Nov 11, 2025, 1:20 PM EST - 6 months ago

REGENXBIO Transcript: Stifel 2025 Healthcare Conference


REGENXBIO Earnings Call Transcript: Q3 2025

Nov 6, 2025, 8:00 AM EST - 6 months ago

REGENXBIO Earnings Call Transcript: Q3 2025


REGENXBIO Announces Presentation at the World Muscle Society

Sep 29, 2025, 7:05 AM EDT - 8 months ago

REGENXBIO Announces Presentation at the World Muscle Society


REGENXBIO Earnings Call Transcript: Q2 2025

Aug 7, 2025, 8:00 AM EDT - 9 months ago

REGENXBIO Earnings Call Transcript: Q2 2025


REGENXBIO Transcript: Status Update

Jun 5, 2025, 8:00 AM EDT - 1 year ago

REGENXBIO Transcript: Status Update


maphere
maphere May. 13 at 6:38 PM
$RGNX ABBVIE investing big $$$ into the PH3 wAMD trial, look at the global sites being added and preparing for commercialization. Abbvie doesn't say much at their ER about this but this is where a lot of $$$ is going right now. Hope to hear some news tomorrow. https://clinicaltrials.gov/study/NCT07007065?term=abbv-rgx-314&viewType=Card&rank=5&tab=history&a=60&b=61&compareMode=sideBySide#version-content-panel
3 · Reply
explover
explover May. 13 at 5:09 PM
$RGNX so basically if interim results (n=13) from March 11, 2026 replicate on the pivotal sample (n=30), this goes to $18-24 on day one and then further I suppose we are afraid of a single SAE?
1 · Reply
cold_beef_cake
cold_beef_cake May. 13 at 3:52 PM
$RGNX Not trading like a company that's about to hit it out of the park.
2 · Reply
RobbyAxelrod1
RobbyAxelrod1 May. 13 at 3:40 PM
$RGNX Sold ill wait for tomorrow usually news seeps in by now doesn't look to good here.
2 · Reply
maphere
maphere May. 13 at 2:37 PM
$RGNX Another webinar on the 19th...3 hours long.
1 · Reply
murphylaw
murphylaw May. 13 at 2:24 PM
$RGNX should be $12 by 4PM?
1 · Reply
buymoremakemore
buymoremakemore May. 12 at 11:45 PM
$RGNX Rarely any bears on here coming into data readout. Short float 15%. Not bad
0 · Reply
Timefortendies77
Timefortendies77 May. 12 at 10:55 PM
$RGNX Hi RGNX ---it's your pals over at $BHVN. What's the word on getting your drug reassessed given the change in FDA leadership?
2 · Reply
Timefortendies77
Timefortendies77 May. 12 at 10:53 PM
$BHVN Remember this tweet? @US_FDA exploring path forward for therapies that received CRLs $BHVN , $RGNX , Sydnexis held meetings w FDA’s chief counsel, Sean Keveney, following high-profile regulatory setbacks. Such meetings are highly unusual, writes BioCentury Washington Editor https://x.com/jeff_cranmer/status/2039127714599440671
0 · Reply
murphylaw
murphylaw May. 12 at 5:59 PM
$RGNX Epic pop in store tomorrow. Buckle up!
0 · Reply
Wolfman5960
Wolfman5960 May. 12 at 4:57 PM
$RGNX Looks like Makary is officially out and Kyle Diamantas will be the acting commissioner. https://www.politico.com/news/2026/05/12/makary-fda-resign-white-house-00916014
2 · Reply
Find_the_Cure
Find_the_Cure May. 12 at 4:03 PM
$RGNX This should be up HUGELY since the AI stocks are seeing outflows today. It’s now or never.
0 · Reply
maphere
maphere May. 12 at 2:15 PM
$RGNX Good sign, coming May 20th: Parent Project Muscular Dystrophy Please join PPMD for a community webinar on May 20th at 1:00 PM ET with REGENXBIO, who will share topline results from the pivotal portion of the AFFINITY DUCHENNE trial evaluating RGX-202, the company’s investigational gene therapy for #Duchenne #musculardystrophy. REGENXBIO will review key findings from the pivotal study, including data on microdystrophin expression and interim safety and functional outcomes. Learn more, submit questions in advance, and register now: https://www.facebook.com/plugins/post.php?href=https%3A%2F%2Fwww.facebook.com%2Fparentprojectmd%2Fposts%2Fpfbid06dycaiyWeCdv52K75Diu7LVv1bkfk3mznDRc7uyWdg3RSYwCjAgRRpm3wDFAgpHql&show_text=true&width=500
3 · Reply
derkatch83
derkatch83 May. 12 at 4:38 AM
$RGNX guess yesterday’s drop was a reaction for CEO selling shares. But it was the automatic planned transaction, so no bearish signal to me
3 · Reply
Find_the_Cure
Find_the_Cure May. 11 at 7:45 PM
$RGNX LOFL
0 · Reply
Find_the_Cure
Find_the_Cure May. 11 at 7:03 PM
$RGNX what a turd
0 · Reply
OppieMax
OppieMax May. 11 at 5:12 PM
$RGNX Am I buying this ahead of Thursday? Seems like a good risk/reward setup for a small punt, no?
2 · Reply
Find_the_Cure
Find_the_Cure May. 11 at 4:25 PM
$RGNX WTF happened here today?
1 · Reply
murphylaw
murphylaw May. 11 at 2:03 PM
$RGNX Easy money. Should be $20 on Thursday.
2 · Reply
Ml55totoag
Ml55totoag May. 9 at 1:04 AM
$RGNX very nice again!
2 · Reply
Wolfman5960
Wolfman5960 May. 8 at 8:35 PM
$RGNX Update on the FDA commissioner situation. Looks like Kyle Diamantas may take over as acting commissioner and actual nominees for commissioner look like it may be former FDA ​commissioner Stephen Hahn or former acting commissioner and ​assistant Health Secretary Brett Giroir. https://www.reuters.com/world/white-house-considering-naming-fda-food-chief-acting-commissioner-sources-2026-05-08/
0 · Reply
Ml55totoag
Ml55totoag May. 8 at 8:04 PM
$RGNX this is in utube.
0 · Reply